News

OBD’s listing on The London Stock Exchange published widely in the media.

 

Oxford University biotech firm heads for float on AIM - The Daily Telegraph

Oxford BioDynamics float sparks payout for university - Evening Standard

Oxford BioDynamics to list on London's junior market - Reuters

Oxford BioDynamics placing has raised gross proceeds £20m - Bloomberg Headlines

Oxford BioDynamics Plans AIM listing, raises GBP20 million to expand - Wall Street Journal/Dow Jones

Oxford University biotech spin-off to float on AIM - Proactive Investor

Oxford BioDynamics raises GBP7.1 million ahead of AIM Admission - TD Direct Investing

Oxford BioDynamics applies to trade on AIM, completes oversubscribed placing - Mergermarket

Oxford BioDynamics to float on London's AIM market on 6 December - Mergermarket

Details revealed about biotechnology firm float - Insider Media

Oxford BioDynamics raises GBP7.1 million ahead of AIM admission - Alliance News

Oxford BioDynamics aims for $25m flotation - Global University Venturing

Oxford BioDynamics is planning an IPO - ACQ5

 

The Atlantic publishes "Genes Are Overrated". This article points to higher order genome organisation.

Genes Are Overrated. Higher order genome conformation studied by EpiSwitch™ technology are growing trends in understanding genetics and genomics.

OBD signs Master Agreement with one of the world's leading global biotechnology companies to characterise Multiple Sclerosis patients from healthy patients.

OBD's EpiSwitch technology, EpiSwitchTM, will also be utilised to differentiate disease severity.

In collaboration with the Ludwig Institute for Cancer Research, OBD publishes its work using the EpiSwitch™ technology to develop non-invasive stratification markers for melanoma.

The EpiSwitchTM platform monitors the epigenetic state of organisms by detecting and accessing a novel class of cellular biomarkers - chromosome conformation signatures. Available at: "Chromatin barcodes as biomarkers for melanoma". Pigment Cell Melanoma Res. 2014 Sep; 27(5):788-800

OBD contributes a chapter to the newly published "Clinical and Statistical Consideration in Personalized Medicine”.

The chapter outlines the current developments used to investigate the function epigenetics plays in understanding personalized medicine. CRC Press. Editors: Claudio Carini (Pfizer); Sandeep Menon (Pfizer), Mark Chang (AMAG Pharmaceuticals). Book available at: CRC Press website. A review of the book was published in  Journal of Biopharmaceutical Statistics.

OBD and major European Pharma sign agreement to identify regulatory events underlying the carcinogenic process induced by Non-genotoxic carcinogenesis (NGC).

OBD will use their EpiSwitch™ Discovery Platform to resolve epigenetic knowledge around the carcinogenic process induced by Non-genotoxic carcinogenesis (NGC). The data will be integrated with transcriptional profiling data to mechanistically and functionally characterize this process and develop a new class of potential NGC biomarkers.

OBD and major US Pharma sign agreement to develop epigenetic knowledge and biomarkers to be used in the development of treatments for Lymphoma.

Resolution of the mechanisms that lead to the formation of lymphoma using the EpiSwitch™ Discovery Platform should lead to defined treatments for lymphoma.

OBD and major US Pharma sign agreement to differentiate Alzheimer’s disease (AD) patients from other cognitive impaired patients.

OBD will identify epigenetic changes based on chromosome conformation signatures that will be able to identify Alzheimer’s disease (AD) patients from whole blood using OBD’s EpiSwitch™ Discovery Platform.

Formation of distinct chromatin conformation signatures epigenetically regulate macrophage activation.

A collaboration between Oxford BioDynamics and Professor Siamon Gordon (Oxford University), has utilised EpiSwitch™ technology for successful identification of regulatory chromosome conformation signatures as epigenetic biomarkers for innate, alternative and classical activation states in macrophages stimulated with LPS, IL-4 and IFN-γ. Available at: International Immunopharmacology 2014 Jan;18(1):7-11

Dr. Alexandre Akoulitchev presents a poster at the 12th annual Northeast ALS Consortium (NEALS).

Each year NEALS holds an annual conference to review current ALS research, discuss potential new therapies, and prepare member-sites for clinical trials in ALS. Dr. Alexandre Akoulitchev presented this poster on the "Development of novel ALS treatment on the basis of mechanisms of cellular chronological life span control" in October 2013. 

Professor Jane Mellor gives a talk at the Cold Spring Harbour Laboratory.

Prof Mellor presented at the thirteenth meeting on transcriptional regulation in eukaryotes at CSHL in August 2013.

Summary of the talk:

In yeast, antisense transcription (AST) acts as a "reset" button for gene expression by influencing the chromatin structure at the gene promoter and over the coding region.

The AST-mediated chromatin structures in the coding region of genes facilitates transcription bursting, the major generator of noise in biological systems. This is complemented by the AST-mediated dynamic chromatin structures at the promoter which explain state changes; the capacity to dynamically switch genes from the "off" to the "on" state, also contributing to stochastic expression, and the activation or repression of gene expression.

 

OBD signs a major contract with the University of Glasgow.

Oxford Biodynamics has signed a major contract with the University of Glasgow to develop epigenetic deregulation know how and biomarkers to be used to differentiate between RA patients, healthy controls and responders/non-responders to methotrexate (MTX).

OBD signs an extension of its Collaboration Agreement with a major Japanese Pharmaceutical Company.

Oxford Biodynamics signs an extension of its Collaboration Agreement with a major Japanese Pharmaceutical Company under which Oxford Biodynamics Pte Limited, a wholly owned subsidiary of Oxford Biodynamics based in Singapore, to conduct an extended non-invasive test for breast cancer using Japanese samples.

Genome Institute of Singapore (GIS) and Oxford Biodynamics Pte (OBD) have signed a major Collaboration Agreement to develop EpiSwitch™ technology for epigenetic stem cell differentiation.

GIS and OBD, a wholly owned subsidiary of Oxford Biodynamics Limited, have signed a Collaboration Agreement to jointly develop the EpiSwitchTM technology to create a focused EpiSwitchTM epigenetic signature to compare IPSCS, ESCS and Progenitor cell lines.

OBD and major US Pharma announce agreement to differentiate lymphoma subgroups.

Oxford BioDynamics Limited has entered into a Technology and Evaluation Agreement with a second major US Pharmaceutical Company to identify EpiSwitchTM signatures using their EpiSwitchTM Biomarker discovery platform in order to differentiate Diffuse Large B-cell Lymphoma (DLBCL) prognostic subgroups.

OBD announces signature of a Development Agreement with Janssen Research & Development.

(Oxford, UK and Philadelphia, USA) - Oxford BioDynamics Limited and Janssen Research & Development, LLC. have signed an agreement for the use of the EpiSwitchTM platform technology in the development of epigenetic cancer biomarkers for circulating tumour cells (CTCs).

The development agreement will focus initially on EpiSwitchTM biomarkers signatures for the non-invasive detection of CTCs for high performance diagnostic and prognostic stratifications in patients with prostate cancer. Christian Hoyer Millar, CEO of Oxford BioDynamics said that “Oxford BioDynamics are delighted to have the opportunity of working with Janssen to accelerate the development of a new treatment for prostate cancer”.

Annual Meeting of Japanese Association of Breast Cancer Screening, Okinawa. In a prospective study EpiSwitch™ technology identifies a patient who develops breast cancer two years ahead of confirmation.

Okinawa. November 10, 2012. At the Annual Meeting of the Japanese Association of Breast Cancer Screening, Dr Nomizu presented the results of the EpiSwitchTM analysis, conducted by OBD in collaboration with Otsuka Pharmaceutical Co. Limited. A prospective study has been conducted on the patient, who was diagnosed as healthy by both mammography and ultrasonic examination, but was identified with deregulation, symptomatic of breast cancer, by the EpiSwitchTM technology. Observations carried out over a two year period confirmed that the patient had developed stage 1 breast cancer, with a tumour size of 15 mm.

OBD presents at the Next Generation Sequencing for Research and Clinical Genomics Conference, Basel, Switzerland (September 24-25).

OBD presented a Next Generation Sequencing (NGS) extension of its EpiSwitchTM technology platform. This technological innovation offers an unbiased discovery of EpiSwitchTM biomarkers. The new approach has been validated for melanoma and was supported by the latest results from OBD for the development and cross-validation of the OBD melanoma test.

This novel approach offers an unprecedented scope for the identification and classification of biomarkers for the stratification of the most challenging clinical conditions, while retaining the unique utility of the EpiSwitchTM read-out.

The data was presented within the Epigenetic Session in a talk entitled "Chromatin Loops, Epigenetics & NGS: Data Driving Biomarkers" by the Company CSO, Dr Alexandre Akoulitchev.

OBD completes melanoma clinical meta-trial.

OBD has completed a validation trial of its EpiSwitchTM melanoma test, stratifying melanoma patients from non-melanoma skin cancer patients - Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC) and other skin lesions. Whole venous blood samples of 116 melanoma and 170 non-melanoma skin cancer patients were analysed in the study. The multivariate molecular biomarker test included 15 epigenetic biomarkers and shows high accuracy, sensitivity and PPV.

OBD identifies biomarkers for Nasopharyngeal carcinoma (NPC).

OBD announces the completion of the pilot study and discovery of EpiSwitch™ biomarkers for NPC.

Nasopharyngeal carcinoma (NPC), a cancer originating in the nasopharynx, is a significant concern in certain regions of East Asia where incidences can reach up to 30/100,000 people. The causes of an increased risk for NPC in these regions are not entirely clear, it is understood that there are both epigenetic and genetic factors implicated in its causation and almost all forms of NPC are associated with EBV infection. NPC produces few symptoms early in its course, with the result that most cases are quite advanced when detected. With this in mind, OBD carried out a pilot study on blood samples from Filipino and Singaporean populations with NPC using its EpiSwitch™ technology. Biomarkers from three loci - DLC1, DLEC-1, and RASSF1A showed particularly promising results, differentiating samples from NPC patients and controls, and will be utilised in the final design of the diagnostic test.

The OBD EpiSwitch™ pilot study for Parkinson’s disease completed successfully.

After Alzheimer’s disease, Parkinson’s disease (PD) is the most common, neurodegenerative condition affecting around 0.5-1% of the population between the ages of 65-69. OBD has evaluated the epigenetic read-outs on the loci of the genetic, epigenetic, and protein markers that had been previously identified and independently linked to Parkinson’s disease using the EpiSwitch™ platform technology. Biomarkers suitable for differentiation between PD patients and controls were identified including biomarkers in the loci highly sensitive microtubule-associated protein tau (MAPT), α-synuclein (SNCA) and serine/arginine repetitive matrix 2 (SRRM2). This led to a complete and accurate discrimination between the two groups and shows the utility of this test for further development of a PD diagnostic.

The OBD EpiSwitch™ Alzheimer’s pilot study brings hope for early diagnosis and intervention.

There are an estimated 5.4 million people with Alzheimer’s disease (AD) in the United States and this number is expected to increase to 13.2 million by 2050. The lack of an accurate early diagnostic method to detect AD adds significant social and economic costs. Currently, $183 billion is spent yearly on Alzheimer’s associated costs.

A pilot study was set up to detect the presence of blood biomarkers for systemic epigenetic changes utilising the EpiSwitch™ platform technology. The EpiSwitch™ technology identified the presence of valid biomarkers in key signature genes associated with Alzheimer’s disease, including amyloid precursor protein (APP), apolipoprotein E (APOE) and phosphatidylinositol-binding clathrin assembly protein (PICALM).

 

OBD Prostate Cancer Clinical Trial Completed.

OBD has completed a clinical trial using the EpiSwitchTM technology, to stratify prostate cancer patients with the most aggressive prostate cancer that is at a high risk of spreading from those with less aggressive prostate cancer that can be suitably managed with less invasive treatments.This test will help physicians and patients to make better decisions about the patient's treatment regime.

Completion of clinical trial for the EpiSwitch™ technology, differentiating Melanoma from Non-Melanoma skin cancers, Basal Cell Carcinoma and Squamous Cell Carcinoma.

Oxford BioDynamics has completed its validation trial and demonstrated high accuracy for its  EpiSwitchbased test to differentiate Melanoma from Non-Melanoma skin cancers, Basal Cell Carcinoma and Squamous Cell Carcinoma.

The EpiSwitch™ technology can differentiate the least aggressive from more aggressive prostate cancers.

Oxford BioDynamics has completed a test development using the EpiSwitch technology, to differentiate the least aggressive cases of prostate cancer from those that are more aggressive. Least aggressive tumours are categorized as Gleason score 4-6 and either Stage I/II or from patients older than 65, whilst more aggressive cases are Gleason grade 7 and above, and either Stage III+ or less than 65 years old. The test can accurately identify the two groups, providing essential information for physicians to determine whether patients require observation or intervention.

Oxford BioDynamics announces completion results for the EpiSwitch™ Breast Cancer test.

Oxford BioDynamics announces completion of the results of the EpiSwitch Breast Cancer test on a cohort of 236 samples spanning different grade of cancer, tumour size, lymph node involvement, hormone receptor and HER2 status. The test demonstrates high accuracy and is performed under high standards of ISO 13485:2003, ISO 9001:2008 and FDA 21 CFR Part 820 requirements.

Results announced of validation trial for non-invasive breast cancer screening test.

Oxford BioDynamics announces the results of its validation trial for a non-invasive breast cancer screening test. The blood-based test demonstrates high accuracy for patients with all five sub-types of breast cancer - Luminal A, Luminal B, Her2+, Basal and Unclassified.

Collaboration Agreement signed with CERBM and IGBMC, France.

Oxford BioDynamics signs a Collaboration Agreement with Centre Européen de Recherche en Biologie et en Médecine (CERBM) and the Institute de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), France.

Oxford BioDynamics sponsors Summer School on Chromatin & Transcription, Greece.

Oxford BioDynamics sponsors Summer School on Chromatin and Transcription, Spetses Island, Greece, and its key-note speaker Dr Ramin Shiekhattar (Center for Genomic Regulation, Barcelona).